Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 8/20 | 0.67 |
| ▸ | PFKFB4 | Q16877 | 7/20 | 0.67 |
| ▸ | SLC16A3 | O15427 | 6/20 | 0.64 |
| ▸ | CMA1 | P23946 | 3/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552003 | 0.91 | PFKFB4 (0.61) | PFKFB3PFKFB4SLC16A3CMA1HTR6 | |
| SCHEMBL3555875 | 0.88 | PFKFB3 (0.83) | PFKFB3PFKFB4CMA1 | |
| SCHEMBL3553890 | 0.88 | PFKFB4 (0.72) | PFKFB3PFKFB4SLC16A3CMA1HTR6 | |
| SCHEMBL3553777 | 0.86 | PFKFB3 (0.77) | PFKFB3PFKFB4CMA1HTR6 | |
| SCHEMBL3559705 | 0.85 | PFKFB3 (0.68) | PFKFB3PFKFB4CMA1HTR6 | |
| SCHEMBL3562877 | 0.85 | PFKFB4 (0.70) | PFKFB3PFKFB4CMA1HTR6 | |
| SCHEMBL3884692 | 0.81 | PFKFB3 (0.71) | PFKFB3PFKFB4CMA1HTR6 | |
| SCHEMBL788108 | 0.81 | PFKFB4 (1.00) | PFKFB3PFKFB4CMA1 | |
| SCHEMBL3559885 | 0.80 | PFKFB3 (0.65) | PFKFB3PFKFB4CMA1HTR6 | |
| Propane SCHEMBL28642185 | 0.80 | PFKFB4 (0.94) | PFKFB3PFKFB4CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | PFKFB3 1209/4885PFKFB4 1018/4885SLC16A3 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.